Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To study incident diabetic polyneuropathy (DPN) prospectively during the first 13 years after a screening-based diagnosis of type 2 diabetes and determine the associated risk factors for the development of DPN. RESEARCH DESIGN AND METHODS: We assessed DPN longitudinally in the Danish arm of the Anglo-Danish-Dutch study of Intensive Treatment of Diabetes in Primary Care (ADDITION) using the Michigan Neuropathy Screening Instrument questionnaire (MNSIQ), defining DPN with scores ≥4. Risk factors present at the diabetes diagnosis associated with the risk of incident DPN were estimated using Cox proportional hazard models adjusted for trial randomization group, sex, and age. RESULTS: Of the total cohort of 1,533 people, 1,445 completed the MNSIQ at baseline and 189 (13.1%) had DPN at baseline. The remaining 1,256 without DPN entered this study (median age 60.8 years [interquartile range 55.6; 65.6], 59% of whom were men). The cumulative incidence of DPN was 10% during 13 years of diabetes. Age (hazard ratio [HR] 1.03 [95% CI 1.00; 1.07]) (unit = 1 year), weight (HR 1.09 [95% CI 1.03; 1.16]) (unit = 5 kg), waist circumference (HR 1.14 [95% CI 1.05; 1.24]) (unit = 5 cm), BMI (HR 1.14 [95% CI 1.06; 1.23]) (unit = 2 kg/m2), log2 methylglyoxal (HR 1.45 [95% CI 1.12; 1.89]) (unit = doubling), HDL cholesterol (HR 0.82 [95% CI 0.69; 0.99]) (unit = 0.25 mmol/L), and LDL cholesterol (HR 0.92 [95% CI 0.86; 0.98]) (unit = 0.25 mmol/L) at baseline were significantly associated with the risk of incident DPN. CONCLUSIONS: This study provides further epidemiological evidence for obesity as a risk factor for DPN. Moreover, low HDL cholesterol levels and higher levels of methylglyoxal, a marker of dicarbonyl stress, are identified as risk factors for the development of DPN.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neuropathic pain can lead to interference with daily activities, disability, psychosocial impairment, and reduced health-related QoL.547,552,562,563”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“The earliest affected nerve fibers are usually the small myelinated and unmyelinated fibers; thus, the most common early symptoms are pain and dysesthesias (unpleasant sensations of burning).547,554,555”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“Characteristically, the pain is burning, lancinating, tingling, or shooting (electric shock-like), with paresthesia, occurring in varying combinations, and is typically worse at night547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“However, the presence of atypical features including motor deficits greater than sensory, asymmetry of symptoms and signs, and rapid progression warrant a timely referral.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [547]
37 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602 · cited 2×
“DPN increases the risk of chronic pain, falls, foot ulcers, and amputations; it also negatively affects the quality of life (3).”
BackgroundResultSelf-citationDyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482 · cited 1×
“Of these, diabetic polyneuropathy (DPN) is the most common complication (2).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Self-citationFeldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Self-citationDiabetic neuropathy: clinical manifestations and current treatments
Callaghan, B. C., Cheng, H. T., Stables, C. L., Smith, A. L., & Feldman, E. L. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70065-0 · Cited by 1,211
Self-citationThe global burden of diabetes and its complications: an emerging pandemic
Susan van, D., Beulens, J. W. J., Yvonne T. van der, S., Grobbee, D. E., & Nealb, B. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000368191.86614.5a · Cited by 874 · cited 2×
“patients with diabetes over the course of their lives (1,4,5).”
BackgroundAdvances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy
Tesfaye, S., & Selvarajah, D. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2239 · Cited by 615 · cited 1×
“Other metabolic syndrome components such as obesity, hypertension, low HDL cholesterol, and hypertriglyceridemia are among the potential additional risk factors for the development of DPN (6,8,10).”
Background
Cited by
Items 201–257 of 257
Tang, D., Gu, X., Xuan, Y., Liu, Q., & Lu, L. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s535989 · Cited by 2
Huang, S., Lan, Y., Zheng, C., Liang, H., Wei, Y., & Chen, B. (2025) · BMC Neurology · doi:10.1186/s12883-025-04379-y · Cited by 1
“In the Danish ADDITION T2DM cohort, peripheral neuropathy is associated with decreased HDL-C [38].”
Peng, J., Xue, D., Li, J., Wei, L., & Wang, Y. (2026) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s573535 · Cited by 1
“4,5 Moreover, DPN often presents insidiously.”
Neuropatía diabética y su relación con la calidad de vida en pacientes con diabetes tipo 2
Ramírez, J. R. A., Castañón, D. L., Ordoñez, O. I. V., Velázquez, H. S. C., García, M. D. C. A., & Granjeno, M. C. O. (2026) · Atención Primaria · doi:10.1016/j.aprim.2026.103454 · Cited by 1
Baum, P., Kosacka, J., & Ebert, T. (2026) · Neurological Research and Practice · doi:10.1186/s42466-026-00466-8 · Cited by 1
“In addition to duration of diabetes, the prevalence also appears to be associated with other risk factors, such as obesity and the metabolic syndrome [41, 42].”
Velichkova, A. N., Mutlu-Smith, M., Hall, A. L., & Torsney, C. (2026) · PAIN Reports · doi:10.1097/pr9.0000000000001430 · Cited by 2
“However, in the clinic, female sex is a significant risk factor for painful diabetic neuropathy 2,13 and females report more severe pain symptoms.”
Savelieff, M. G., Bennett, D., Jensen, T. S., & Feldman, E. L. (2026) · Annals of Neurology · doi:10.1002/ana.78289 · Cited by 1
“28 DD2 recapitulated these fi ndings, with BMI and WC linked to PN prevalence ratio, adjusted for age, sex, and even diabetes duration.”
InfluentialSelf-citationHamdaoui, M. S., Midoun, N., & Belhadj, M. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.08.005 · Cited by 1
Intelligenza Artificiale per la cura del diabete mellito: opportunità e prospettive future
(2024) · il Diabete · doi:10.30682/ildia2304g · Cited by 1
Risk factors for corneal nerve fiber loss in Chinese patients with type 2 diabetes mellitus
Huang, L., Chen, X., Xiao, Z., Wu, K., Wang, L., & Liu, L. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112304 · Cited by 1
Protein Pyrrole Adducts in Diabetes Mellitus
Chen, X., Jiang, Z., & Spencer, P. S. (2022) · Biomarkers in disease · doi:10.1007/978-3-031-08014-2_52 · Cited by 1
Neuropathy in Type 1 and Type 2 Diabetes
Akıncı, G., Nowacek, D. G., & Callaghan, B. C. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_4 · Cited by 1
Self-citationBashir, B., Iqbal, Z., Schofield, J. D., & Soran, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00012-7 · Cited by 1
Callaghan, B. C., Gallagher, G., Fridman, V., & Feldman, E. L. (2020) · Diabetologia · doi:10.1007/s00125-020-05233-1 · Cited by 1
Self-citationAbdelhafiz, A. H., & Sinclair, A. J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch55
MOHAMMED, M. D. M. M. M. N. T., & Kyrillos, F. A. (2020) · The Medical Journal of Cairo University/The Medical Journal of Cairo University · doi:10.21608/mjcu.2020.110943
Diabetische Neuropathie – Relevanz metabolischer Phänotypen
Bönhof, G., & Ziegler, D. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00686-9
“Bei Teilnehmern ausschließlich mit Typ-2-Diabetes fand sich in der ADDITION-Denmark-StudieeineAssoziation zwischen demNeuauftreten einer diabetischen Neuropathie innerhalb von 13 Jahren und Übergewicht, Taillenumfang, BMI (Body-Mass-Index), niedrigeren HDL-Cholesterin-Spiegeln (HDL: „high density lipoprotein“) sowie a…”
BackgroundIdentificação de AGEs na saliva como método de diagnóstico do diabetes mellitus
Muraoka, M. Y. (2021) · doi:10.14393/ufu.di.2020.859 · Cited by 1
Diabetic neuropathy: the “anesthetized” complication
Bax, G. (2021) · The Journal of AMD · doi:10.36171/jamd21.24.1.7
Sztanek, F., Jakab, Á. A., Jebelovszki, É., Gaszner, B., Páll, D., Kempler, P., & Harangi, M. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.16
“A már említett ADDITION-Denmark vizsgálat 1533 betegadatának feldolgozása alapján az alacsony HDL-C-szint a diabeteses polyneuropathia független prediktora.(45) A HDL-C-szint és a CAN összefüggésére vonatkozóan jóval kevesebb adat áll rendelkezésünkre.”
Protein Pyrrole Adducts in Diabetes Mellitus
Chen, X., Jiang, Z., & Spencer, P. S. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-81303-1_52-1
Rastreamento da Polineuropatia Distal Simétrica em pacientes com obesidade
Pereira, L. C. R., Romani, F. A. D. P., Dantas, L. B. P., Carvalho, A. R. T. B., Vieira, A. R. S. D. A., & Pedrosa, H. C. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e12351.2023
Lozeron, P. (2024) · EMC - Neurologia · doi:10.1016/s1634-7072(24)48980-0
Andrea, P. J. (2024) · Pesci Egyetemi Archivum (University of Pécs) · doi:10.15170/pte.2024.016
The Genetics of Diabetic Neuropathy
YÜCEL, Z., & YÜKSEL, E. B. (2023) · doi:10.69860/nobel.9786053359111.39
Tharani, G., Paul, J., Alagesan, J., & Harikrishnan, N. (2025) · Neuroscience Research Notes · doi:10.31117/neuroscirn.v8i1.389
Proporción de polineuropatía diabética y sus posibles factores asociados
Ruiz, M. Á., Cifuentes, M., Fuentes, M. A. B., Mora, J., Bohórquez-Ballén, M. C., & Silva, M. (2025) · Universitas Médica · doi:10.11144/javeriana.umed66.ppdp
Modern approaches to the diagnosis of diabetic polyneuropathy: innovations and prospects
Sova, S., Sofilkanych, N. V., Pukaliak, I., & Palahuta, H. V. (2025) · Ukrainian Neurological Journal · doi:10.30978/unj2025-1-15
Modern approaches to the diagnosis of diabetic polyneuropathy: innovations and prospects
Buletsa, B. A., & Sofilkanych, N. V. (2025) · Experimental and Clinical Medicine · doi:10.35339/ekm.2025.94.1.bus
Painful diabetic polyneuropathy in patients with cerebrovascular diseases
Tanashyan, M. М., Антонова, К. В., & Панина, А. А. (2025) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202512507164
Genetikai tényezők szerepe a diabéteszes neuropátia kialakulásában
Hajdú, N., Tordai, D. Z., Rácz, R., Ludvig, Z., Vági, O. E., Békeffy, M. Z., Körei, A. E., Istenes, I., Kempler, P., & Putz, Z. (2025) · Diabetologia Hungarica · doi:10.24121/dh.2025.17
Davalos, L., Pasnoor, M., Dimachkie, M. M., & Barohn, R. J. (2025) · Neurologic Clinics · doi:10.1016/j.ncl.2025.05.006
Adili, A., Aikemu, M., Rana, K. S., Wei, Y., Yusufu, A., & Jiang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-19922-7
Xu, F., Zhao, L.-H., Wang, X.-H., Wang, C.-H., Yu, C., Zhang, X.-L., Ning, L.-Y., Huang, H.-Y., Su, J., & Wang, X.-Q. (2022) · Figshare · doi:10.6084/m9.figshare.19092606
Xu, F., Zhao, L.-H., Wang, X.-H., Wang, C.-H., Yu, C., Zhang, X.-L., Ning, L.-Y., Huang, H.-Y., Su, J., & Wang, X.-Q. (2022) · Figshare · doi:10.6084/m9.figshare.19092609
Mohammedi, K., Harrap, S., Mancia, G., Marre, M., Poulter, N. R., Chalmers, J. P., & Woodward, M. (2021) · Figshare · doi:10.6084/m9.figshare.13520701
Lian, X., Qi, J., Yuan, M., Li, X., Wang, M., Li, G., Yang, T., & Zhong, J. (2023) · Figshare · doi:10.6084/m9.figshare.23827021
Lian, X., Qi, J., Yuan, M., Li, X., Wang, M., Li, G., Yang, T., & Zhong, J. (2023) · Figshare · doi:10.6084/m9.figshare.23827018
Lian, X., Qi, J., Yuan, M., Li, X., Wang, M., Li, G., Yang, T., & Zhong, J. (2023) · Figshare · doi:10.6084/m9.figshare.23827015
Xu, F., Zhao, L.-H., Wang, X.-H., Wang, C.-H., Yu, C., Zhang, X.-L., Ning, L.-Y., Huang, H.-Y., Su, J., & Wang, X.-Q. (2022) · Figshare · doi:10.6084/m9.figshare.19092612
Lian, X., Qi, J., Yuan, M., Li, X., Wang, M., Li, G., Yang, T., & Zhong, J. (2023) · Figshare · doi:10.6084/m9.figshare.23827027
Lian, X., Qi, J., Yuan, M., Li, X., Wang, M., Li, G., Yang, T., & Zhong, J. (2023) · Figshare · doi:10.6084/m9.figshare.23827024
Association between obesity-related indicators and peripheral neuropathy in type 2 diabetes mellitus
Ji, H., Cui, J., Zhang, Y., Ma, Q., Hu, X., Deng, H., 陈烁苹, Zhou, Q., Pan, W. H., Hong, J., et al. (2026) · BMC Endocrine Disorders · doi:10.21203/rs.3.rs-8230770/v1
Association of Type 2 Diabetes Subgroups With Incident Peripheral Neuropathy
Simpkins, K. S., Balasubramanyam, A., Pilla, S. J., Bertoni, A. G., Chen, H., Mielke, M. M., Usoh, C. O., Wagenknecht, L. E., Espeland, M. A., & Bancks, M. P. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0051
Zhao, Y., Wang, L., & Feng, D. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70199
“Studies have indicated that the risk of DPN in type 2 diabetes patients correlates positively with diabetes duration, highlighting the clinical signi fi cance of early intervention to delay progression 28,29 .”
Scott, N. V., Yadav, S., Mahmood, N. A., & Rumora, A. E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1769812
Nerve Under Siege: Managing Diabetic Neuropathy and Pain
Alom, S., Ali, F., Abubakar, M., Yogi, S., & Bhat, H. R. (2026) · Springer eBooks · doi:10.1007/978-981-95-8946-3_3
Khalil, H., Al.hawash, M., Al.athamna, M., & Arnous, R. A. (2026) · Research Square · doi:10.21203/rs.3.rs-9765614/v1
Ibrahim, A. M., Abdelrazik, R. K., Zedan, A., Alshimy, A. M., Abdelrahim, R. M., Moubarak, E., Nassar, R. N., Ammaar, A. H. F., & Shalash, K. (2026) · Retos · doi:10.47197/retos.v81.119409
“Andersen et al. (2018), in a 13-year prospective cohort, identified elevated BMI as a predictor of incident DPN independent of glycemic control.”
Feijuan, K., Wang, Z., Yang, Q., Wu, J., Tang, S., Gu, M., Ding, X., & Wang, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1829752
“Notably, high rates of CAN are also found in individuals with newly diagnosed T2DM and in youth with either T1DM or T2DM (25 – 27).”
Research progress and clinical application of biomarkers in neuropathic pain
Zhang, L., Zhuang, H., Ma, M., Xian, S., Zhang, W., Bi, H., Ji, S., & Huang, R. (2026) · The Journal of Headache and Pain · doi:10.1186/s10194-026-02489-7
Anastasiou, G., Παπάνας, Ν., Barkas, F., Tentolouris, N., Liamis, G., Michalis, L. K., Bechlioulis, A., Kalaitzidis, R., Mantzoros, C. S., & Liberopoulos, E. N. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113494
Anastasiou, I. A., Tentolouris, N., & Rebelos, E. (2026) · HORMONES · doi:10.1007/s42000-026-00826-8
Mitochondrial dysfunction in diabetic neuropathy: a core pathogenic hub and therapeutic implications
Wu, X., Li, X., Lou, N.-J., 庄向华, & Chen, S. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-09015-y
“…is one of the most common and debilitating complications of diabetes; approximately half of all people with diabetes will experience some degree of nerve damage during the course of their illness, with the risk of developing the condition increasing as the duration of the disease lengthens [1–4].”
Diabetic Polyneuropathy Patients Exhibit an Altered Skeletal Muscle Proteome Phenotype
Thybo, F. F., Khan, K. S., Jakobsgaard, J. E., Andersen, H., Vissing, K., & Palmfeldt, J. (2026) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.70060
“…composition and adiposity should be considered as obesity is known to impact mitochondrial proteins across multiple tissues [ 57 ], as being overweight is likely to be a risk factor for polyneuropathy [ 58, 59 ], and therefore the higher BMI in the DPN group of this study might influence the DPN.”
Self-citationZheng, X., Yang, K., Qu, R., Peng, X., & Yang, L. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70473
Metadata
- Authors
- Andersen, S. T., Witte, D. R., Dalsgaard, E.-M., Andersen, H., Nawroth, P., Fleming, T., Jensen, T. M., Finnerup, N. B., Jensen, T. S., Lauritzen, T., Feldman, E. L., Callaghan, B. C., & Charles, M.
- Affiliations
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Michigan (US)
- Corresponding author
- Andersen, Signe T.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-02-27
- Volume
- 41
- Issue
- 5
- Pages
- 1068-1075
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2790769408
- Cited by
- 248
- References
- 41
- Citations by year
- 2026: 16 · 2025: 38 · 2024: 36 · 2023: 38 · 2022: 28 · 2021: 37 · 2020: 29 · 2019: 17 · 2018: 9
- FWCI
- 15.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Novo Nordisk (Novo Nordisk Foundation Challenge Programme grant)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Keywords
- diabetic polyneuropathy, type 2 diabetes, risk factors, Michigan Neuropathy Screening Instrument, methylglyoxal, HDL cholesterol, LDL cholesterol, waist circumference, body mass index, age, weight, diabetes screening, primary care, neuropathy prevention, intensive diabetes treatment, cumulative incidence, long-term follow-up
- MeSH terms
- Aged, Denmark, Diabetes Mellitus, Type 2, Diabetic Neuropathies, Female, Follow-Up Studies, Humans, Male, Mass Screening, Middle Aged, Obesity, Primary Health Care, Risk Factors, Cohort Studies, Incidence, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.